LyondellBasell Industries NV (LYB) Stock Price Today
Aura AI Summary
Key Stats
- $21.34BMarket Cap
- -Volume
- Basic MaterialsSector
- $82.3852W High
- $42.2852W Low
- -Typical Hold Time
- $32.93BEnterprise Value
- 4.18%Div Yield
- -Trading Activity
Track LyondellBasell Industries NV (LYB) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, LyondellBasell Industries NV has traded between a low of $42.28 and a high of $82.38, highlighting its annual price range. Buy and sell LyondellBasell Industries NV shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Most Recent News
Scotiabank raises Simon Property Group price target to $222 after strong Q2 results and higher full-year guidance.
Scotiabank raised its price target for Simon Property Group to $222 from $220 while maintaining a neutral Sector Perform rating. The real estate trust reported a 19.5% revenue increase to $1.79 billion in Q2 2026, with stable 96% occupancy at its U.S...

UiPath CEO Daniel Dines sells 1.4M shares for $22.5M
UiPath CEO Daniel Dines has sold 1.4 million shares of the company, raising $22.5 million. This move may indicate a personal liquidity event or portfolio rebalancing by the CEO. Investors might watch for any impact on the stock price or future inside...

Hims & Hers faces federal lawsuit and price target cut amid legal scrutiny over billing and data practices
Hims & Hers Health is under federal investigation and lawsuit for alleged deceptive billing, difficult subscription cancellations, and unauthorized sharing of health data with advertisers. Barclays lowered its price target from $39 to $35, reflecting...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.